For research use only. Not for therapeutic Use.
Alconil (Al 1567)(CAT: I021744) is a potent aldose reductase inhibitor widely studied for its therapeutic potential in chronic obstructive pulmonary disease (COPD) and diabetes-related complications. By targeting aldose reductase, a key enzyme in the polyol pathway, it helps mitigate oxidative stress and inflammation associated with hyperglycemia and COPD. Alconil (Al 1567) is valuable for research exploring novel treatments for diabetic neuropathy, retinopathy, and other metabolic disorders. Its high purity and efficacy make it an essential tool for advancing understanding of aldose reductase’s role in disease progression and therapeutic intervention strategies.
Catalog Number | I021744 |
CAS Number | 97677-19-5 |
Synonyms | Alconil; Al 1567; Al-1567; Al1567 |
Molecular Formula | C15H9FN2O2 |
Purity | 98% |
Solubility | Soluble in DMSO |
Appearance | Solid powder |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
IUPAC Name | 2-fluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione |
InChI | InChI=1S/C15H9FN2O2/c16-8-5-6-10-9-3-1-2-4-11(9)15(12(10)7-8)13(19)17-14(20)18-15/h1-7H,(H2,17,18,19,20) |
InChIKey | JRGBXEJDIMXJAP-UHFFFAOYSA-N |
SMILES | O=C1NC2(C(N1)=O)C3=C(C4=C2C=CC=C4)C=CC(F)=C3 |